[en] [en] BACKGROUND: Spinal muscular atrophy (SMA) results from a loss-of-function mutation in the SMN1 gene. SMA patients suffer progressive motor disability, although no intellectual impairments have been described. Three drugs have been recently approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These drugs result in longer life expectancy for SMA type 1 (SMA1) patients.
OBJECTIVE: The objective of the study was to assess longitudinally the psychomotor development of patients with SMA1 treated after the symptom onset and of patients treated presymptomatically.
DESIGN: Longitudinal, monocentric, noninterventional, prospective study.
METHODS: Our study included 11 SMA1 patients and seven presymptomatic SMA patients. The SMA1 patients were treated with an approved drug beginning after onset of symptoms; treatment for the presymptomatic patients was begun before symptom onset. They were longitudinally evaluated between September 2018 and January 2022 using the Bayley Scales of Infant and Toddler Development™ - Third Edition.
RESULTS: At each time point, all patients treated presymptomatically scored above those treated postsymptomatically on the motor scale. The cognitive scores of six of the seven patients treated presymptomatically were average; one patient was in the low average range. In the 11 postsymptomatically treated patients, four scored either in the low average or the abnormal range on the cognitive scale, but a positive trend was observed during the follow-up.
CONCLUSION: A significant proportion of patients treated postsymptomatically scored below average on cognitive and communicative scales, with most significant concerns raised about the age of 1 year. Our study indicates that intellectual development should be considered as an important outcome in treated SMA1 patients. Cognitive and communicative evaluations should be performed as part of standard of care, and guidance should be provided to parents for optimal stimulation.
Disciplines :
Pediatrics
Author, co-author :
Ngawa, Magali ; Université de Liège - ULiège > Département de Psychologie > Psychologie du développement cognitif normal et atypique
Dal Farra, Fabian ; Université de Liège - ULiège > Département des Sciences de l'activité physique et de la réadaptation > Kinésithérapie générale et réadaptation
Marinescu, Andrei-Dan; Division of Child Neurology, Centre de Références des Maladies Neuromusculaires, Department of Pediatrics, University Hospital Liège & University of Liège, Liège, Belgium ; Department of Pediatric Neurology, 'Alexandru Obregia' Psychiatry Hospital, Bucharest, Romania
Servais, Laurent ; Université de Liège - ULiège > Département des sciences cliniques ; MDUK Neuromuscular Center, Department of Paediatrics, University of Oxford, Oxford, UK
Language :
English
Title :
Longitudinal developmental profile of newborns and toddlers treated for spinal muscular atrophy.
Moultrie RR Kish-Doto J Peay H, et al. A review on spinal muscular atrophy: awareness, knowledge, and attitudes. J Genet Couns 2016; 25: 892–900.
Lefebvre S Bürglen L Frézal J, et al. The role of the SMN gene in proximal spinal muscular atrophy. Hum Mol Genet 1998; 7: 1531–1536.
Verhaart IEC Robertson A Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review. Orphanet J Rare Dis 2017; 12: 124.
Dangouloff T Botty C Beaudart C, et al. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J Rare Dis 2021; 16: 47.
von Gontard A Zerres K Backes M, et al. Intelligence and cognitive function in children and adolescents with spinal muscular atrophy. Neuromuscul Disord 2002; 12: 130–136.
Mix L Schreiber-Katz O Wurster CD, et al. Executive function is inversely correlated with physical function: the cognitive profile of adult spinal muscular atrophy (SMA). Orphanet J Rare Dis 2021; 16: 10.
Sieratzki JS Woll B. Toddling into language: precocious language development in motor-impaired children with spinal muscular atrophy. Lingua 2002; 112: 423–433.
Ramdas S Servais L. New treatments in spinal muscular atrophy: an overview of currently available data. Expert Opin Pharmacother 2020; 21: 307–315.
Finkel RS Mercuri E Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017; 377: 1723–1732.
Mendell JR Al- Zaidy S Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 2017; 377: 1713–1722.
Baranello G Darras B Day J, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med 2021; 384: 915–923.
Dangouloff T Servais L. Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives. Ther Clin Risk Manag 2019; 15: 1153–1161.
Dangouloff T Burghes A Tizzano EF, et al. 244th ENMC international workshop: newborn screening in spinal muscular atrophy May 10–12, 2019, Hoofdorp, The Netherlands. Neuromuscul Disord 2020; 30: 93–103.
Dangouloff T Vršcˇaj E Servais L, et al. Newborn screening programs for spinal muscular atrophy worldwide: where we stand and where to go. Neuromuscul Disord 2021; 31: 574–582.
Bayley N. Bayley scales of infant and toddler development (BSID-III). 3rd ed. Antonio, TX: Harcourt Assessment Inc., 2006.
Boemer F Caberg J-H Beckers P, et al. Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium. Sci Rep 2021; 11: 19922.
Pane M Donati MA Cutrona C, et al. Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening. Eur J Pediatr 2022; 181: 2821–2829.
De Vivo DC Bertini E Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord 2019; 29: 842–856.
Strauss KA Farrar MA Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the phase III SPR1NT trial. Nat Med 2022; 28: 1390–1397.
Strauss KA Farrar MA Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial. Nat Med 2022; 28: 1381–1389.
Aragon-Gawinska K Seferian AM Daron A, et al. Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: a cohort study. Neurology 2018; 91: e1312–e1318.
Dangouloff T Hiligsmann M Deconinck N, et al. Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening. Dev Med Child Neurol 2023; 65: 67–77.
Zappa G LoMauro A Baranello G, et al. Intellectual abilities, language comprehension, speech, and motor function in children with spinal muscular atrophy type 1. J Neurodev Disord 2021; 13: 9.
Fluss J Lidzba K. Cognitive and academic profiles in children with cerebral palsy: a narrative review. Ann Phys Rehabil Med 2020; 63: 447–456.
Zimmerman FJ Christakis DA Meltzoff AN. Associations between media viewing and language development in children under age 2 years. J Pediatr 2007; 151: 364–368.
Laufersweiler-Plass C Rudnik-Schöneborn S Zerres K, et al. Behavioural problems in children and adolescents with spinal muscular atrophy and their siblings. Dev Med Child Neurol 2003; 45: 44–49.
Lenzoni S Semenza C Calligaro D, et al. Cognitive profiles and clinical factors in type III spinal muscular atrophy: a preliminary study. Neuromuscul Disord 2022; 32: 672–677.
Masson R Brusa C Scoto M, et al. Brain, cognition, and language development in spinal muscular atrophy type 1: a scoping review. Dev Med Child Neurol 2021; 63: 527–536.
Hoshi Y Sasaki C Yoshida K, et al. Milestones for communication development in Japanese children with spinal muscular atrophy type I. J Health Sci 2017; 14: 115–120.
Mendonça RH Rocha AJ Lozano-Arango A, et al. Severe brain involvement in 5q spinal muscular atrophy type 0. Ann Neurol 2019; 86: 458–462.
Ebbink BJ Aarsen FK van Gelder CM, et al. Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy. Neurology 2012; 78: 1512–1518.
Ebbink BJ Poelman E Aarsen FK, et al. Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain. Dev Med Child Neurol 2018; 60: 579–586.
Yohannan M Patel P Kolawole T, et al. Brain atrophy in Werdnig-Hoffmann disease. Acta Neurol Scand 1991; 84: 426–428.
Harding BN Kariya S Monani UR, et al. Spectrum of neuropathophysiology in spinal muscular atrophy type I. J Neuropathol Exp Neurol 2015; 74: 15–24.
Wishart TM Huang JP-W Murray LM, et al. SMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy. Hum Mol Genet 2010; 19: 4216–4228.
